While the dates are only guidelines / estimates as the trial can be stopped early for overwhelming efficacy it clearly demonstrates that the company needs to finalise a lucrative partnership deal as we simply don’t have the cash runway to accomodate these timelines no matter what cost cutting has been done or what is being said in CCs or on HC
https://www.clinicaltrials.gov/study/NCT06325566?intr=Rexlemestrocel-L&rank=3
2024 Here we go again., page-241
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |